VEPPANU™ (vepdegestrant): A First-in-Class FDA-Approved Breast Cancer Treatment Using PROTAC Technology
VEPPANU is prescribed for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has worsened after at least one type of endocrine therapy. Breast cancer cells in this subtype depend on estrogen signals to grow. Over time, many tumors develop ESR1 mutations, which can make standard hormone therapies stop working.


